Blues’ Early Cost-Effectiveness Study Raises TEC-nical Difficulties – Thoratec
This article was originally published in The Gray Sheet
Executive Summary
BlueCross BlueShield Technology Evaluation Center's April cost-effectiveness analysis of LVAD for destination therapy was premature, Thoratec VP-Reimbursement Robin Bostic asserted June 29
You may also be interested in...
Congress Must Develop Cost Criteria For Coverage Decisions – NEJM Article
Legislators should establish "reasonable and necessary" criteria for national coverage decisions that consider cost effectiveness, according to medical ethicist Murial Gillick, MD, Harvard Medical School
Heart Assist Device Payment Rate Aligns With Transplants Under CMS Rule
CMS proposes to increase the median reimbursement rate for left-ventricular assist devices to $125,000, or 30% over last year's level, under the FY 2005 inpatient prospective payment system (IPPS) proposed rule, released May 11
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.